Fabiflu 200/400mg

Favipiravir inhibited the replication of viral genome which was the most manifested in the middle of viral proliferation cycle in a timeofdrugaddition test Antiviral activity of favipiravir was attenuated in the presence of purine nucleosides or purine bases indicating competition of favipiravir with purine nucleosides rather than pyrimidine nucleosides Madin Darby Canine Kidney MDCK cells are well used as an in vitro assay of influenza virus MDCK cells were treated with favipiravir and cellular metabolites were analyzed by HPLC Favipiravir ribofuranosyl5 triphosphate favipiravirRTP favipiravir ribofuranose favipiravirR and favipiravir ribofuranosyl5monophosphate favipiravirRMP were detectedThese results suggest that the activation of favipiravir takes place once it is incorporated into cells FavipiravirRTP was chemically synthesized and was tested for the inhibition of RNA polymerase activity of influenza virus as assessed by incorporation of PGTP FavipiravirRTP inhibited the viral RNA polymerase activity in concentrations ranging from nanomolar to micromolar None of favipiravir and favipiravirRMP affected influenza RNAdependent RNA polymerase RdRp at 100 molL These results indicate that favipiravir exerts its antiviral activity as a prodrug since favipiravir is intracellularly phosphoribosylated to be an active form favipiravirRTP which inhibits the viral replication by interacting with viral RNA polymerase